The study is for patients with advanced kidney cancer, known as renal cell carcinoma (RCC), that has spread to other parts of the body. It compares two combinations of drugs: botensilimab and balstilimab versus ipilimumab and nivolumab. These drugs are part of a treatment called immunotherapy, which helps your immune system fight cancer. The study aims to include 120 patients and will last for up to 96 weeks. During this time, doctors will watch for side effects and see how well the cancer responds to treatment.
- Participants will need to visit the clinic regularly for check-ups and treatment.
- The study lasts up to 96 weeks, depending on your response to treatment.
- Risks include possible side effects from the drugs, which will be closely monitored.
To join, you must be at least 18, have a type of RCC, and meet specific health criteria. You cannot join if you have had certain previous treatments or health issues. If you are considering joining, please discuss it with your doctor to understand the benefits and risks.